VivoSeq
Neurology

Trigeminal Neuralgia

27

Pipeline Programs↗

14

Active Trials↗

14

Companies Involved↗

Trigeminal Neuralgia is an emerging landscape with 27 programs across 14 companies. The most active players are Pfizer, Shanghai SIMR Biotechnology Co., Ltd., Merz Pharmaceuticals GmbH. 6 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

15/100

Mech. Concentration

45/100

Completion Rate

65/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 2S

Shanghai SIMR Biotechnology Co., Ltd.

1 program

Phase 2M

Merz Pharmaceuticals GmbH

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 3R

Revance Therapeutics, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

34 of 36 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody13%Cell therapy13%

Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 92% of 39 pipeline programs.

Analysis

Trial Status

37

clinical trials

Completed13 · 35%
Recruiting6 · 16%
Active, not recruiting4 · 11%
Terminated4 · 11%
Unknown status3 · 8%
Not yet recruiting3 · 8%
Other4 · 11%

Clinical Trials

Trial Activity

37 trials

Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia
Recruiting·—·N/A·NCT06890897·174 enrolled
Pregabalin as an add-on Therapy to Carbamazepine in Trigeminal Neuralgia Patients
Recruiting·PPostgraduate Institute of Dental Sciences Rohtak·N/A·NCT06357260·50 enrolled
Safety and Efficacy of Botulinum Toxin A in Patients With Trigeminal Neuralgia
Recruiting·—·Phase 3·NCT06315790·80 enrolled
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells Exosomes for Trigeminal Neuralgia
Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05152368·20 enrolled
Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia
Recruiting·HHospital Universitari de Bellvitge·N/A·NCT06851910·20 enrolled
OnabotulinumtoxinA for Trigeminal Neuralgia
Recruiting·SStanford University·Phase 4·NCT06216886·20 enrolled
Comparison b/w Carbamazepine vs Oxcarbazepine in Treatment of Trigeminal Neuralgia
Active, not recruiting·—·N/A·NCT07252453·122 enrolled
Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia
Active, not recruiting·SShanghai SIMR Biotechnology Co., Ltd.·Phase 2·NCT06571448·138 enrolled
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
Active, not recruiting·NNoema Pharma AG·Phase 2/3·NCT05217628·166 enrolled
Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia
Active, not recruiting·JJinnah Postgraduate Medical Centre·Phase 4·NCT06849219·122 enrolled
The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia
Not yet recruiting·—·N/A·NCT06977932·126 enrolled
The Synergism and Attenuation Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia
Not yet recruiting·—·N/A·NCT07074561·28 enrolled
Efficacy and Safety of Oral Antiviral Drug Combined With Carbamazepine Versus Celecoxib Combined With Carbamazepine in the Treatment of Idiopathic Trigeminal Neuralgia: A Multicenter, Randomized Controlled Trial
Not yet recruiting·BBeijing Tiantan Hospital·Preclinical·NCT07673549·165 enrolled
Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia
Enrolling by invitation·LLKGS_277·Phase 2·NCT06410859·240 enrolled
Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia
Completed·TThomas Jefferson University·N/A·NCT00203229·20 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)